The Engineering Chemical Technology Center (ECTC) has officially received its first state registration certificate for a product of its own manufacture — beta-propiolactone (BPL). This reagent is a critical component for the Russian pharmaceutical industry, enabling the production of inactivated vaccines. The issued document confirms the substance’s compliance with safety standards and permits its free circulation in Russia and the Customs Union countries.
A Key Component for Safe Vaccines
Beta-propiolactone is indispensable in the production of vaccines against influenza, hepatitis A, rabies, measles, and rubella, as well as veterinary vaccines. BPL’s uniqueness lies in its mechanism of action: the reagent selectively destroys the virus’s genetic material while leaving its protein envelope absolutely intact. This allows for the creation of highly effective and maximally safe vaccines that form a reliable immune response.
Tomsk Capacities: Benchmark Purity and Meeting Market Demand
The project was implemented with grant support from the Agency for Technological Development. The technical documentation was developed by scientists from the Faculty of Chemistry at Tomsk State University (TSU), with ECTC acting as the engineering partner and manufacturer. The pilot plant launched in Tomsk can synthesize up to 1,000 liters of BPL per year.
According to experts, this volume is capable of fully covering the current needs of the entire Russian pharmaceutical market for this raw material. The product’s quality matches the best global standards.
Quality Indicators of Tomsk BPL:
- Substance purity: 99.6% (confirmed by standard sample certification in October 2025);
- Stability: The high degree of purification guarantees the preservation of properties throughout the entire shelf life;
- Leader’s trust: The reagent is already included in the register of approved suppliers for the Fort company (part of the Nacimbio holding, Rostec State Corporation).
Import Independence and National Security
Using local beta-propiolactone from a Russian manufacturer allows pharmaceutical companies to radically reduce logistical risks and eliminate dependence on unstable foreign supplies. Obtaining the state registration certificate guarantees the legal purity and stable characteristics of the raw material. In the long term, this will ensure the uninterrupted production of essential medicines and strengthen Russia’s national drug security.
